As hay fever symptoms spike, here's how to set the right bedtime routine. Plus how to keep pollen out of the room you sleep in.
Biotech IPOs have shown signs of a rebound this year, but a string of poor post-debut performances have tempered expectations of a full market recovery. It is looking to raise up to $317.7 million in the IPO by offering nearly 17.7 million shares at a price range of $16 and $18 each. South San Francisco, California-based Alumis will enter the market on the heels of therapy developer Rapport Therapeutics' strong market debut earlier this month.
Friday, the FDA granted accelerated approval to Bristol Myers Squibb & Co’s (NYSE:BMY) Krazati (adagrasib) in combination with cetuximab as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC), who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) res